Nitrite Inhalants: History, Epidemiology, and Possible Links

Total Page:16

File Type:pdf, Size:1020Kb

Nitrite Inhalants: History, Epidemiology, and Possible Links - - I - I- I M Nitrite Inhalants: History, Epidemiology, and Nitrite 'in'alat's have been commonly :abused sR e&insla the nIted tates. Possible Links to AIDS Nitre ixa m s a npopular topic in the early 1980sX tecu of Harry W Haverkos, Andrea N. Kopstein,1 Hank Wilson, and Peter Drotman3 AIDSWas not k Wn.Withthe discovery of 1National Institute on Drug Abuse, Rockville, MD 20857, USA; 2Committee to Monitor HIV, concern about nitrite use in the USA Poppers, San Francisco, CA 94102 USA; and 3National Center for Infectious Diseases, waned. However nitrite inhalant use is Centers for Disease Control and Prevention, Atlanta, GA 30333 USA asoiae wit baaiorl reaaeadt.t.n.mX.g......w...`n ad.`HgaZ..HWnWl t dKcre£'.L''p te. cn. an natural Nitrite inhalants are commonly abused the package insert is angina pectoris (17). killer cel activity in a few labitory stud- substances in the United States, primarily Amyl nitrite is used experimentally to treat ies, d t:r a c ec tor in by homosexual men and others who use cyanide poisoning. The drug produces the patdge-nesis of AIbS-rele Kaposi's nitrites to facilitate sexual intercourse methemoglobin, which has a high affinity sarcomia. Discourap g ir :continues and/or produce euphoria (1-4). Scientific for cyanide, and leads to the production of to be a wordiwhll&pubiic healthjI.il Key in o.rd: AD5 HI infection' Inimunosup- interest nitrites increased in the 1980s cyanomethemoglobin, releasing cyanide pressio.... Kpoi's. sarcoma, nitrite due to their possible links to AIDS (5-11). from cell mitochondrial cytochrome oxidase ;$ ir behaor. Envmn Health In this paper we review the history, appli- sites, where it is otherwise destructive (18). Perspect 102:858-861 (1994) cations, and prevalence of use of nitrite When amyl nitrite became difficult to inhalants. We present the hypotheses link- procure for nonmedical or recreational pur- ing their use to AIDS. We provide sugges- poses during the 1970s, there was a prolif- mia, intoxication, and, rarely, death (15). tions to physicians, community leaders, eration of butyl nitrite products by non- Other effects include development of policymakers, and researchers on what they pharmaceutical manufacturers (15). Butyl habitual use patterns, tolerance, and burns can do to limit the use of nitrites. nitrites were marketed as "liquid incense" resulting from inadvertent ignition of the or "room odorizers." Because the labels on vapor. The National Toxicology Program History and Clinical Uses bottles containing butyl nitrites stated that of the National Institute of Environmental The alkyl nitrites (e.g., amyl, butyl, iso- they were not to be inhaled and no health Health Sciences evaluated mice and rats propyl) are colorless or yellow liquids at claim was made, the FDA never had juris- exposed short term (6 hr/day for 14 days room temperature and are highly volatile. diction over this product as it does medi- and 13 weeks) to inhaled isobutyl nitrite at They are esters of nitrous acid that have a cine and many foods. concentrations ranging from 0 to 800 ppm fruity odor (often described as unpleasant) The legal status of some key nitrite and noted several adverse effects. Rats and have been nicknamed "poppers" because preparations has changed in the past few exposed to greater than 600 ppm died dur- of the sound made when glass capsules con- years. One development prompting this ing the 14-day studies. At lower exposure taining amyl nitrite are crushed (12). change has been the description of several levels, the most striking lesion seen in mice The vasodilatory effect following acute and chronic adverse effects attributed was hyperplasia of the nasal mucosa and inhalation of amyl nitrite vapor was to the abuse of nitrite inhalants (15). In bronchial and bronchiolar tree. described in 1859 and led to the first response to those reports, the U.S. Methemoglobinemia was confirmed. report of its clinical application to provide Congress enacted a ban on the manufac- Other adversely affected organs included relief for angina pectoris in 1867 (13,14). ture and retail sale of butyl nitrites (except the liver, spleen, thymus, and bone mar- In the 1880s, butyl nitrites were found to when used in specified chemical commer- row (19). have similar vasodilatory qualities, but cial processes) in the Anti-Drug Abuse Act these compounds were never developed for of 1988 (Public Law 100-690, Section Prevalence ofNonmedical Nitrite Use clinical use (12). 2404). The law specified that the Con- Alkyl nitrites are among the most com- Amyl nitrite was initially marketed as a sumer Product Safety Commission (not the monly used inhalants in the United States. prescription drug in the United States in FDA) would enforce the ban. However, to Other commonly abused inhalants are 1937 and remained a prescription drug circumvent the clear intent of the law, nitrous oxide, gasoline, glues, and solvents, until September 1960, when the Food and nitrite manufacturers began to sell other such as paint thinners. The National Drug Administration (FDA) eliminated nitrite alkyl congeners, such as isopropyl Institute on Drug Abuse has collected the prescription requirement. In the 1960s, nitrite, as "new and improved" room odor- information concerning nitrite inhalant nitroglycerin sublingual tablets, dermally izers. In 1990, Congress outlawed manu- use among high school seniors since 1979. applied ointments, and, later, transdermal facture and sale of alkyl nitrites in the Eleven percent of high school seniors patches began to replace amyl nitrite as the Omnibus Crime Bill (Public Law 101-647, interviewed in 1979 reported ever using preferred treatment for angina pectoris. In Section 3202). Since then, at least one nitrites. Use has decreased consistently the late 1960s, pharmacists and drug man- manufacturer has developed a cyclohexyl among seniors since 1980, to 1.5% for the ufacturers noticed widespread purchases of nitrite inhalant and marketed it diversely. class of 1992 (20). amyl nitrite by apparently healthy young According to chemical nomenclature, According to national surveys, self- men. These over-the-counter purchases cyclohexyl nitrites are not in the same class reported amyl and butyl nitrite use varies became the impetus for the FDA to rein- as alkyl nitrites and therefore may not be by gender, region, and race. Male high state the prescription requirement in 1968. banned under current federal law. school seniors reported higher rates of Since then an underground market for Underground manufacturers and importers amyl nitrite has emerged (15). For the last continue to market butyl and isopropyl few years, there has been no medical adver- nitrites illegally. Address correspondence to H. W. Haverkos, tising for pharmaceutical-grade amyl nitrite, The acute toxicity of inhaled and Room 1OA-38, NIDA, 5600 Fishers Lane, Rockville, MD 20857 USA. and it is no longer listed in the Physician's ingested nitrites in humans includes skin We thank Peter Delany, William Grace, and Desk Reference (16). irritations (especially around the nose and Vincent Smeriglio for reviewing the paper and Amyl nitrite remains available by pre- lips), tracheobronchial irritation, headache, providing helpful comments. scription. The clinical indication listed in hypotension, cyanosis, methemoglobine- Received 2 June 1994; accepted 25 July 1994. 858 Environmental Health Perspectives I .. s i 1i 1ifi S M M Mfi&EF1diJIl1&-fj- A g-. inhalant use and nitrite use than females. heterosexual men and women who did not day for 3 or 18 days on the immune sys- The proportion of males who used nitrites consistently report using nitrites. In 1983 tems of 18 male volunteers. One inhala- at least once was typically twice the per- and 1984, human immunodeficiency virus tion of amyl nitrite (0.18, 0.36, or 0.48 centage of females reporting lifetime use (HIV) was discovered and reported as the ml) was administered from a closed 4-1 (20). The highest rate of nitrite use report- cause of AIDS (31,32). Subsequently, flask at 3-hr intervals each day of study. ed by high school seniors in 1979 was in three other hypotheses suggesting nitrites After full exhalation, the subject inhaled the Northeast, and the lowest rate was as promoting factors in AIDS have been from the flask through the mouthpiece reported in the West. Rates have decreased proposed. First, nitrites have been pro- with the nose "clipped" and held at full markedly in all regions, with the highest posed to enhance HIV transmission by inspiration for 5 sec before exhalation. rates in 1992 reported in the North- their association with risky sexual behaviors Blood was drawn for immune profile Central United States and the lowest rates and HIV infection among gay men. immediately after the last inhalation and 1, in the Northeast (21). Second, nitrite use has been associated 4, and 7 days later. Modest depression of Nitrite use varies by race/ethnicity as with immune suppression and thus might T-lymphocyte counts and natural killer cell well as geographic area. Although hasten the onset of symptomatic disease. activity were noted with a rebound to at racial/ethnic data are not available for high Third, nitrite inhalant use has been associ- least baseline levels several days after the school seniors, the Public Health Service- ated with the development ofAIDS-related last inhalations. Cell proliferation respons- sponsored National Household Survey Kaposi's sarcoma. es to phytohemagglutinin (PHA), con- provides limited population-based esti- Nitrites and Sexual Behavior/HIV canavalin A (Con A), and pokeweed mito- mates. Self-reported nitrite use in 1991 was Transmission. Several studies have linked gen (PWM) were unaffected by amyl highest for white males in each of six nitrite use with risky sexual behavior nitrite inhalation (36). selected metropolitan areas for which data and/or HIV infection among gay men. Ross and Drew (37) interviewed 97 gay were analyzable.
Recommended publications
  • S J. Braz. Chem. Soc., Vol. 22, No. 2, 352-358, 2011
    J. Braz. Chem. Soc., Vol. 22, No. 2, 352-358, 2011. Printed in Brazil - ©2011 Sociedade Brasileira de Química S 0103 - 5053 $6.00+0.00 Short Report Synthesis and Antileishmanial Activity of New 1-Aryl-1H-Pyrazole-4- Carboximidamides Derivatives Maurício S. dos Santos,a Adriana O. Gomes,a Alice M. R. Bernardino,*,a Marcos C. de Souza,a Misbahul A. Khan,b Monique A. de Brito,c Helena C. Castro,d Paula A. Abreu,d Carlos R. Rodrigues,e Rosa M. M. de Léo,f Leonor L. Leonf and Marilene M. Canto-Cavalheirof aPrograma de Pós-Graduação em Química Orgânica and dLABioMol, GCM - IB, Universidade Federal Fluminense, Outeiro de São João Baptista, 24020-150 Niterói-RJ, Brazil bChemistry Department, The Islamia University of Bahawalpur, 63100 Bahawalpur, Pakistan cLaboratório de Química Medicinal Computacional, Faculdade de Farmácia, Universidade Federal Fluminense, 24241-000 Niterói-RJ, Brazil eFaculdade de Farmácia, ModMolQSAR, Universidade Federal do Rio de Janeiro, 24020-150 Rio de Janeiro-RJ, Brazil fLaboratório de Bioquímica de Tripanosomatídeos, IOC, Fundação Oswaldo Cruz, 21040-900 Rio de Janeiro-RJ, Brazil A quimioterapia para as leishmanioses, doenças causadas por protozoários do gênero Leishmania, ainda permanece ineficiente em diversos tratamentos. Portanto, existe a necessidade de pesquisa por novos fármacos. Nesse trabalho, foram sintetizados derivados 1-aril-1H-pirazol- 4-carboximidamidas, avaliadas as atividades leishmanicida e os efeitos citotóxicos in vitro, e realizado um estudo de relação estrutura-atividade (REA) com a série de compostos. O composto 2 apresentou um perfil de atividade que pode ser melhorado através de estratégias de modificação molecular da química medicinal.
    [Show full text]
  • Pneumocystis Pneumonia and Disseminated
    1614 BRITISH MEDICAL JOURNAL VOLUmE 286 21 MAY 1983 Br Med J (Clin Res Ed): first published as 10.1136/bmj.286.6378.1614-a on 21 May 1983. Downloaded from Pneumocystis pneumonia and discussions, and Dr B Jameson and Dr D G Fleck for their valuable assistance disseminated toxoplasmosis in a with the pneumocystis and toxoplasma serology. Ammann A, Cowan M, Wara D, et al. Possible transfusion-associated male homosexual acquired immune deficiency syndrome (AIDS)-California. Morbidity and Mortality Weekly Report 1982;31 :652-4. 2 Du Bois RM, Branthwaite MA, Mikhail JR, et al. Primary pneumocystis Within the past two years 788 cases of the apparently new and carinii and cytomegalovirus infections. Lancet 1981 ;ii: 1339. potentially lethal syndrome of acquired immune deficiency have been Oswald GA, Theodossi A, Gazzard BG, et al. Attempted immune stimula- reported in the United States.' Only three cases have been reported in tion in the "gay compromise syndrome." Br MedJ' 1982;285:1082. the United Kingdom.2-4 We report a case in a previously healthy 37 4 Maurice PDL, Smith NP, Pinching AJ. Kaposi's sarcoma with benign course in a homosexual. Lancet 1982;i:571. year old male homosexual who was initially diagnosed and treated for Task force on acquired immune deficiency syndrome, Centers for Disease pneumocystis pneumonia and subsequently died of widespread Control. Update on acquired immune deficiency syndrome (AIDS)- toxoplasmosis. United States. Morbidity and Mortality Weekly Report 1982;31:507-14. (Accepted 4 March 1983) Case report The patient presented with an eight week history of malaise, non-produc- Departments of Microbiology and Medicine, St Thomas's Hospital, tive cough, night sweats, diarrhoea, anorexia, and weight loss.
    [Show full text]
  • ATSDR Case Studies in Environmental Medicine Nitrate/Nitrite Toxicity
    ATSDR Case Studies in Environmental Medicine Nitrate/Nitrite Toxicity Agency for Toxic Substances and Disease Registry Case Studies in Environmental Medicine (CSEM) Nitrate/Nitrite Toxicity Course: WB2342 CE Original Date: December 5, 2013 CE Expiration Date: December 5, 2015 Key • Nitrate toxicity is a preventable cause of Concepts methemoglobinemia. • Infants younger than 4 months of age are at particular risk of nitrate toxicity from contaminated well water. • The widespread use of nitrate fertilizers increases the risk of well-water contamination in rural areas. About This This educational case study document is one in a series of and Other self-instructional modules designed to increase the primary Case Studies care provider’s knowledge of hazardous substances in the in environment and to promote the adoption of medical Environmen- practices that aid in the evaluation and care of potentially tal Medicine exposed patients. The complete series of Case Studies in Environmental Medicine is located on the ATSDR Web site at URL: http://www.atsdr.cdc.gov/csem/csem.html In addition, the downloadable PDF version of this educational series and other environmental medicine materials provides content in an electronic, printable format. Acknowledgements We gratefully acknowledge the work of the medical writers, editors, and reviewers in producing this educational resource. Contributors to this version of the Case Study in Environmental Medicine are listed below. Please Note: Each content expert for this case study has indicated that there is no conflict of interest that would bias the case study content. CDC/ATSDR Author(s): Kim Gehle MD, MPH CDC/ATSDR Planners: Charlton Coles, Ph.D.; Kimberly Gehle, MD; Sharon L.
    [Show full text]
  • Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics
    Review Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics Joel Mintz 1,†, Anastasia Vedenko 2,†, Omar Rosete 3 , Khushi Shah 4, Gabriella Goldstein 5 , Joshua M. Hare 2,6,7 , Ranjith Ramasamy 3,6,* and Himanshu Arora 2,3,6,* 1 Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Davie, FL 33328, USA; [email protected] 2 John P Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL 33136, USA; [email protected] (A.V.); [email protected] (J.M.H.) 3 Department of Urology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA; [email protected] 4 College of Arts and Sciences, University of Miami, Miami, FL 33146, USA; [email protected] 5 College of Health Professions and Sciences, University of Central Florida, Orlando, FL 32816, USA; [email protected] 6 The Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, FL 33136, USA 7 Department of Medicine, Cardiology Division, Miller School of Medicine, University of Miami, Miami, FL 33136, USA * Correspondence: [email protected] (R.R.); [email protected] (H.A.) † These authors contributed equally to this work. Abstract: Nitric oxide (NO) is a short-lived, ubiquitous signaling molecule that affects numerous critical functions in the body. There are markedly conflicting findings in the literature regarding the bimodal effects of NO in carcinogenesis and tumor progression, which has important consequences for treatment. Several preclinical and clinical studies have suggested that both pro- and antitumori- Citation: Mintz, J.; Vedenko, A.; genic effects of NO depend on multiple aspects, including, but not limited to, tissue of generation, the Rosete, O.; Shah, K.; Goldstein, G.; level of production, the oxidative/reductive (redox) environment in which this radical is generated, Hare, J.M; Ramasamy, R.; Arora, H.
    [Show full text]
  • 2011/149921 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date _ . _ 1 December 2011 (01.12.2011) 2011/149921 Al (51) International Patent Classification: Rahway, New Jersey 07065-0907 (US). HAN, Xiaoqing A01N 43/90 (2006.01) A61K 31/519 (2006.01) [CN/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). GUO, Jian [CN/US]; 126 East Lin (21) International Application Number: coln Avenue, Rahway, New Jersey 07065-0907 (US). PCT/US201 1/037718 GROEPER, Jonathan, A. [US/US]; 126 East Lincoln (22) International Filing Date: Avenue, Rahway, New Jersey 07065-0907 (US). 24 May 201 1 (24.05.201 1) BROCKUNIER, Linda, L. [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). (25) Filing Language: English ROSAUER, Keith [US/US]; 126 East Lincoln Avenue, (26) Publication Langi English Rahway, New Jersey 07065-0907 (US). PARMEE, Emma, R. [US/US]; 770 Sumneytown Pike, West Point, (30) Priority Data: Pennsylvania 19486 (US). 61/349,065 27 May 2010 (27.05.2010) US (74) Common Representative: MERCK SHARP & (71) Applicant (for all designated States except US): MER¬ DOHME CORP.; 126 East Lincoln Avenue, Rahway, CK SHARP & DOHME CORP. [US/US]; 126 East New Jersey 07065-0907 (US). Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). (81) Designated States (unless otherwise indicated, for every (72) Inventors; and kind of national protection available): AE, AG, AL, AM, (75) Inventors/Applicants (for US only): RAGHAVAN, Sub- AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, harekha [US/US]; 126 East Lincoln Avenue, Rahway, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, New Jersey 07065-0907 (US).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,365,574 B2 Raghavan Et Al
    USOO9365574B2 (12) United States Patent (10) Patent No.: US 9,365,574 B2 Raghavan et al. (45) Date of Patent: Jun. 14, 2016 (54) SOLUBLE GUANYLATE CYCLASE (52) U.S. Cl. ACTIVATORS CPC ............ C07D 487/04 (2013.01); A61K3I/519 (2013.01); C07D 519/00 (2013.01) (75) Inventors: Subharekha Raghavan, Teaneck, NJ (58) Field of Classification Search (US); John E. Stelmach, Westfield, NJ CPC ... C07D 487/04; C07D 51.9/00; A61 K31/519 (US); Cameron J. Smith, Lawrenceville, USPC ........................................ 544/280; 514/265.1 NJ (US); Hong Li, Edison, NJ (US); See application file for complete search history. Alan Whitehead, Scotch Plains, NJ (56) References Cited (US); Sherman T. Waddell, Westfield, NJ (US); Yi-Heng Chen, Whippany, NJ U.S. PATENT DOCUMENTS (US); Shouwu Miao, Edison, NJ (US); Olga A. Orinoski, Teaneck, NJ (US); E. A 13:38 SR et al 1 Joie Garfunkle, Metuchen, N(US); 67 A 556 S.E." Xibin Liao, Edison, NJ (US), Jiang 663,772 B1 92003 Schindler et al. Chang, Westfield, NJ (US); Xiaoqing 6,693,102 B2 2/2004 Stasch et al. Han, Edison, NJ (US); Jian Guo, Scotch 6,743,798 B1 6/2004 Straub et al. Plains, NJ (US); Jonathan A. Groeper, 6,844,347 B1 1/2005 Schmidler et al. Metuchen, NJ (US); Linda L. (Continued) Brockunier, Orange, NJ (US); Keith Rosauer, New Hampton, IA (US); FOREIGN PATENT DOCUMENTS Emma R. Parmee, Doylestown, PA (US) CA 2743864 A1 6, 2010 DE 19744O27 A1 10, 1997 (73) Assignee: Merck Sharp & Dohme Corp., (Continued) Rahway, NJ (US) OTHER PUBLICATIONS ( c ) Notice: Subject to any disclaimer, the term of this Search Report and Written Opinion for PCT/US09/064570 filed on patent is extended or adjusted under 35 Nov.
    [Show full text]
  • Nitrocompounds, Aliphatic: Physical & Chemical Properties
    Nitrocompounds, Aliphatic: Physical & Chemical Properties, Encyclopaedia of Occupational Health and Safety, Jeanne Mager Stellman, Editor-in-Chief. International Labor Organization, Geneva. 2011 Chemical Name Colour/Form Boiling Point Melting Molecular Solubility in Relative Density Relative Vapour Inflam. Flash Auto CAS-Number (°C) Point (°C) Weight Water (water=1) Vapour Pressure/ Limits Point (ºC) Ignition Density (Kpa) Point (º C) (air=1) AMYL NITRITE yellowish, transparent 99 117.1 sl sol 0.8828 4.0 110-46-3 liquid 1-CHLORO-1-NITRO- 124.5 109.51 insol 1.2837 ETHANE 598-92-5 2-CHLORO-2-NITRO- liquid 133.6 123.55 0.5 ml sol in 1.197 4.3 8.5 mm Hg 57 ° C oc PROPANE 100 ml @ 20 ° C/20 ° @ 25 ° C 594-71-8 @ 20 ° C C 1-CHLORO-1-NITRO- liquid 143 123.54 0.5ml/100 ml 1.209 0.3 5.8 mm Hg 62 oc PROPANE @ 25 ºC 600-25-9 CHLOROPICRIN slightly oily liquid; 112 -69.2 164.4 sol 1.6558 5.7 5.7 mm Hg 76-06-2 colourless; faint yellow @ 0 º C liquid. 1,1-DICHLORO-1-NI- colourless liquid 124 143.9 0.25 ml/100 m 1.4271 5.0 16.0 mm Hg 76 oc TROETHANE l @ 25 ºC 594-72-9 DIETHYLENE GLYCOL liquid 161 -11.6 sl sol 1.377 DINITRATE @ 25 ºC 693-21-0 ETHYLENE GLYCOL yellowish, oily liquid; 197-200 -22.3 152.06 insol 1.4918 5.24 7 Pa 215 cc 114 DINITRATE colourless 628-96-6 ETHYLENE GLYCOL pale yellow, viscous liquid 197-200 -22.3 152.06 sl sol 1.4978 218 DINITRATE mixed with NITROGLYCERIN (1:1) 53569-64-5 ETHYL NITRATE colourless liquid 87.2 ° C at 762 94.6 ° C 91.07 1.3 g in 100 1.1084 at 20 ° 3.1 lower, 4.0% 10 625-58-1 mm Hg ml C/4 ° C by vol @ 55 ° C ETHYL
    [Show full text]
  • The History of Glyceryl Trinitrate As a Prescription Drug
    patches for transdermal delivery and in tablet form. It ARTICLE may also be injected. Th e history of glyceryl trinitrate as a prescription drug Anthony Butler Abstract A number of prescribed drugs possessing a nitro group (-NO2) are vasodilators and are used to relieve the symptoms of angina pectoris. Th e most widely pre- scribed drug in this group is glyceryl trinitrate (GTN). It was fi rst synthesized by an Italian chemist, Ascanio Sobrero, in 1847. Its clinical use was pioneered by phy- sicians including William Murrell and Sir Th omas Lauder Brunton, and it is now an established remedy for the condition. Its mode of action in vivo was a com- plete mystery until the discovery in the 1980s of nitric oxide (NO) as the naturally occurring messenger mol- ecule that triggers the process of vasodilation. However, exactly how the nitro group in GTN is converted into NO is still uncertain, although the general belief is that an enzyme is responsible. Introduction Th e nineteenth and twentieth centuries witnessed a Figure 1. Ascanio Sobrero. (Source: University of Torino surge in the number of new compounds made in the Archive) laboratory that were available for testing as possible drugs. Not only were the physical properties (colour, GTN was fi rst synthesised by an Italian, Ascanio So- crystal form, melting point and so on) of new com- brero (1812-1888) around 1847. (Figure 1). He was born pounds recorded, but the discoverer might do a few in the small town of Casale Monferrato in the Pied- simple tests to see whether the compound had any in- mont region of Italy and studied medicine at the near- teresting biological properties.
    [Show full text]
  • NITROGYLCERIN and ETHYLENE GLYCOL DINITRATE Criteria for a Recommended Standard OCCUPATIONAL EXPOSURE to NITROGLYCERIN and ETHYLENE GLYCOL DINITRATE
    CRITERIA FOR A RECOMMENDED STANDARD OCCUPATIONAL EXPOSURE TO NITROGYLCERIN and ETHYLENE GLYCOL DINITRATE criteria for a recommended standard OCCUPATIONAL EXPOSURE TO NITROGLYCERIN and ETHYLENE GLYCOL DINITRATE U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE Public Health Service Center for Disease Control National Institute for Occupational Safety and Health June 1978 For »ale by the Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402 DISCLAIMER Mention of company name or products does not constitute endorsement by the National Institute for Occupational Safety and Health. DHEW (NIOSH) Publication No. 78-167 PREFACE The Occupational Safety and Health Act of 1970 emphasizes the need for standards to protect the health and provide for the safety of workers occupationally exposed to an ever-increasing number of potential hazards. The National Institute for Occupational Safety and Health (NIOSH) evaluates all available research data and criteria and recommends standards for occupational exposure. The Secretary of Labor will weigh these recommendations along with other considerations, such as feasibility and means of implementation, in promulgating regulatory standards. NIOSH will periodically review the recommended standards to ensure continuing protection of workers and will make successive reports as new research and epidemiologic studies are completed and as sampling and analytical methods are developed. The contributions to this document on nitroglycerin (NG) and ethylene glycol dinitrate (EGDN) by NIOSH staff, other Federal agencies or departments, the review consultants, the reviewers selected by the American Industrial Hygiene Association, and by Robert B. O ’Connor, M.D., NIOSH consultant in occupational medicine, are gratefully acknowledged. The views and conclusions expressed in this document, together with the recommendations for a standard, are those of NIOSH.
    [Show full text]
  • US5489610.Pdf
    |||||||| US00548961OA United States Patent 19 11 Patent Number: 5,489,610 Fung et al. 45) Date of Patent: 8 Feb. 6, 1996 54 SUSTAINED RELEASE ORGANIC NITRITE 58 Field of Search .................................... 514/506, 509, THERAPY 514/645, 740 75 Inventors: Ho-Leung Fung, Getzville; John A. 56) References Cited Bauer, Williamsville, both of N.Y. U.S. PATENT DOCUMENTS 73 Assignee: Research Foundation of the State 5,278,192 l/1994 Fung et al. .............................. 514f645 University of New York, Albany, N.Y. OTHER PUBLICATIONS * Notice: The portion of the term of this patent Derwent Abstracts 78–35053A, "Medicaments for Treating disclaimed.subsequent to Jan. 11, 2011, has been Cardiardiogenic Shock”, Fribolinis is et al. (1978). Patent Abstracts of Japan, vol. 12, No. 467, Dec. 7, 1988, 21 Appl. No.: 199,280 "Tape Preparation'. 22, PCT Filed: Jun. 30, 1993 Primary Examiner-Frederick Krass Attorney, Agent, or Firm-Kirschstein et al. 86 PCT No.: PCT/US93/06235 (57) ABSTRACT S371 Date: Mar. 1, 1994 A method of treating a patient suffering from a condition S 102(e) Date: Mar. 1, 1994 requiring vasodilator therapy, comprising long term, con 87 PCT Pub. No.: WO94/01103 tinuous adminstration of an organic nitrite to the patient in a dosage form capable of delivering a sufficient therapeutic PCT Pub. Date:Jan. 20, 1994 amount of nitrite to the bloodstream of the patient thereby providing effective vasodilator therapy for at least 24 hours Related U.S. Application Data without the development of tolerance in the patient. The a method of the invention is useful in treating conditions such 63 Continuation-in-part of Ser.
    [Show full text]
  • Georgia State Forensic Drugs
    Comprehensive Forensic FT-IR Collection Library Listing – 4,286 spectra This extensive library contains materials not only of forensic interest but also for general problem solving and identification of unknown substances in industry and academia. The wide range of items include drugs, clandestine lab chemicals, explosives, paints, fabrics, dyes, polymers, inorganic compounds, pigments, adhesives, and other common materials. The library consists of 4,286 spectra that were acquired from a wide range of laboratories involved in forensic investigations. The collection includes the following classes of compounds: • Drugs of abuse, scheduled materials • Pharmaceuticals, vitamins and excipients • Clandestine lab materials and intermediates • Solvents, organic chemicals and hazardous chemicals • Accelerants • Lubricants and natural oils • Explosives, pyrotechnics, primers, powders and boosters • Herbal and plant material and fibers • Automobile paint vehicles, pigments, primers and clear coats • Textiles, natural and man-made fibers, carpet materials • Paints, coatings, varnishes, oils • Dyes and stains • Polymers, monomers, copolymers, plasticizers and rubbers • Inorganics, pigments, minerals and clays • Tape, adhesives, sealants, glues, caulks and putties • Crystal test derivatives and intermediates • Household chemicals, cleaning agents, surfactants and pesticide All spectra were measured using micro or macro Diamond ATR, thin films on salt windows or KBr pellets at 4 cm-1 spectral resolution. Comprehensive Forensic FT-IR Collection Index
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,486,374 B2 Tamarkin Et Al
    USOO8486374B2 (12) United States Patent (10) Patent No.: US 8,486,374 B2 Tamarkin et al. (45) Date of Patent: Jul. 16, 2013 (54) HYDROPHILIC, NON-AQUEOUS (56) References Cited PHARMACEUTICAL CARRIERS AND COMPOSITIONS AND USES U.S. PATENT DOCUMENTS 1,159,250 A 11/1915 Moulton 1,666,684 A 4, 1928 Carstens (75) Inventors: Dov Tamarkin, Maccabim (IL); Meir 1924,972 A 8, 1933 Beckert Eini, Ness Ziona (IL); Doron Friedman, 2,085,733. A T. 1937 Bird Karmei Yosef (IL); Alex Besonov, 2,390,921 A 12, 1945 Clark Rehovot (IL); David Schuz. Moshav 2,524,590 A 10, 1950 Boe Gimzu (IL); Tal Berman, Rishon 2,586.287 A 2/1952 Apperson 2,617,754 A 1 1/1952 Neely LeZiyyon (IL); Jorge Danziger, Rishom 2,767,712 A 10, 1956 Waterman LeZion (IL); Rita Keynan, Rehovot (IL); 2.968,628 A 1/1961 Reed Ella Zlatkis, Rehovot (IL) 3,004,894 A 10/1961 Johnson et al. 3,062,715 A 11/1962 Reese et al. 3,067,784. A 12/1962 Gorman (73) Assignee: Foamix Ltd., Rehovot (IL) 3,092.255. A 6, 1963 Hohman 3,092,555 A 6, 1963 Horn 3,141,821 A 7, 1964 Compeau (*) Notice: Subject to any disclaimer, the term of this 3,142,420 A 7/1964 Gawthrop patent is extended or adjusted under 35 3,144,386 A 8/1964 Brightenback U.S.C. 154(b) by 1180 days. 3,149,543 A 9, 1964 Naab 3,154,075 A 10, 1964 Weckesser 3,178,352 A 4, 1965 Erickson (21) Appl.
    [Show full text]